Please login to the form below
David Khougazian appointed president of Sanofi Pasteur MSD
He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture
Sanofi
Pasteur MSD has appointed David Khougazian as its new president, a role he will
take up on September 1, when he will succeed Dr Jean-Paul Kress at the
Sanofi Pasteur - Merck & Co venture.
Kress, who has led the company since July 2011, will then leave Sanofi Pasteur MSD to join the Sanofi group - which recently announced a major restructuring of its business.
Khougazian moves to the vaccines-focused firm from a position as Sanofi CEO chief of staff, which he held since 2011.
Prior to this he had a number of business operations positions in sales and marketing and as general manager, having joined Rhône-Poulenc (now part of Sanofi) in 1997.
Olivier Charmeil, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur MSD is a major player in the European vaccines market. David's appointment marks a new phase in our development in Western Europe; a challenging and strategic region for our vaccines activity.
“His knowledge of European markets and external stakeholders will be a strong asset to grow Sanofi Pasteur MSD's position in Europe.”
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
